CDKN2A and cancer: The genomic features that are linked to the responses of the two drugs are also biologically relevant (Figure S1.9a); for example, EGFR is the upstream factor of PI3Ks, and the effectiveness of combined CDK4/6 (targets of CDKN2A) and PI3K inhibition has been shown in other cancer models (O’Brien et al., 2020; Bonelli et al., 2017).